Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein, which orchestrates the body's antiviral responses. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the Unit… Read more
Synairgen plc (SYGGF) - Total Liabilities
Latest total liabilities as of December 2024: $1.54 Million USD
Based on the latest financial reports, Synairgen plc (SYGGF) has total liabilities worth $1.54 Million USD as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Synairgen plc - Total Liabilities Trend (2003–2024)
This chart illustrates how Synairgen plc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Synairgen plc Competitors by Total Liabilities
The table below lists competitors of Synairgen plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Solid State Plc
LSE:SOLI
|
UK | GBX46.52 Million |
|
NBEST Prime VIII Inmuebles Socimi SA
MC:YINB8
|
Spain | €15.45K |
|
Mister International Enterprise Corp.
TWO:2941
|
Taiwan | NT$258.76 Million |
|
Dream Impact Trust
TO:MPCT-UN
|
Canada | CA$296.06 Million |
|
Good Energy Group PLC
LSE:GOOD
|
UK | GBX68.01 Million |
|
Caelum Co. Ltd.
KO:258610
|
Korea | ₩65.55 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Synairgen plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Synairgen plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Synairgen plc (2003–2024)
The table below shows the annual total liabilities of Synairgen plc from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $1.54 Million | -1.28% |
| 2023-12-31 | $1.56 Million | -51.94% |
| 2022-12-31 | $3.25 Million | -57.40% |
| 2021-12-31 | $7.64 Million | +124.19% |
| 2020-12-31 | $3.41 Million | +87.40% |
| 2019-12-31 | $1.82 Million | +133.98% |
| 2018-12-31 | $777.00K | -29.56% |
| 2017-12-31 | $1.10 Million | +28.26% |
| 2016-12-31 | $860.00K | -8.12% |
| 2015-12-31 | $936.00K | +89.09% |
| 2014-12-31 | $495.00K | +8.32% |
| 2013-12-31 | $457.00K | +16.88% |
| 2012-12-31 | $391.00K | -35.69% |
| 2010-12-31 | $608.00K | -15.56% |
| 2009-12-31 | $720.00K | +7.95% |
| 2008-12-31 | $667.00K | +14.02% |
| 2007-12-31 | $585.00K | +23.94% |
| 2006-12-31 | $472.00K | +37.21% |
| 2005-12-31 | $344.00K | -13.57% |
| 2004-12-31 | $398.00K | +144.17% |
| 2003-12-31 | $163.00K | -- |